Globus Medical Net Profit Margin 2010-2022 | GMED

Current and historical net profit margin for Globus Medical (GMED) from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue. Globus Medical net profit margin for the three months ending March 31, 2022 was .
Globus Medical Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.96B $0.14B 14.76%
2021-12-31 $0.96B $0.15B 15.55%
2021-09-30 $0.94B $0.19B 19.87%
2021-06-30 $0.93B $0.18B 19.85%
2021-03-31 $0.83B $0.12B 14.67%
2020-12-31 $0.79B $0.10B 12.93%
2020-09-30 $0.77B $0.10B 12.37%
2020-06-30 $0.75B $0.09B 11.90%
2020-03-31 $0.79B $0.15B 18.64%
2019-12-31 $0.79B $0.16B 19.72%
2019-09-30 $0.77B $0.15B 18.96%
2019-06-30 $0.74B $0.14B 19.25%
2019-03-31 $0.72B $0.15B 20.80%
2018-12-31 $0.71B $0.16B 22.05%
2018-09-30 $0.69B $0.14B 20.81%
2018-06-30 $0.68B $0.14B 20.00%
2018-03-31 $0.65B $0.12B 18.20%
2017-12-31 $0.64B $0.11B 16.98%
2017-09-30 $0.61B $0.11B 17.65%
2017-06-30 $0.60B $0.11B 18.12%
2017-03-31 $0.58B $0.11B 18.07%
2016-12-31 $0.56B $0.10B 18.44%
2016-09-30 $0.56B $0.12B 21.26%
2016-06-30 $0.56B $0.12B 21.22%
2016-03-31 $0.55B $0.12B 20.98%
2015-12-31 $0.55B $0.11B 20.70%
2015-09-30 $0.53B $0.10B 19.36%
2015-06-30 $0.51B $0.10B 19.49%
2015-03-31 $0.49B $0.10B 19.68%
2014-12-31 $0.48B $0.09B 19.58%
2014-09-30 $0.46B $0.09B 18.66%
2014-06-30 $0.45B $0.08B 18.44%
2014-03-31 $0.44B $0.07B 15.58%
2013-12-31 $0.43B $0.07B 15.67%
2013-09-30 $0.42B $0.07B 16.19%
2013-06-30 $0.41B $0.06B 15.69%
2013-03-31 $0.40B $0.08B 19.14%
2012-12-31 $0.39B $0.07B 19.12%
2012-09-30 $0.37B $0.07B 17.91%
2012-06-30 $0.36B $0.07B 18.73%
2012-03-31 $0.35B $0.06B 17.82%
2011-12-31 $0.33B $0.06B 16.92%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $5.873B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.627B 21.80
Edwards Lifesciences (EW) United States $60.552B 42.53
Alcon (ALC) Switzerland $35.080B 30.59
STERIS (STE) Ireland $21.113B 26.67
Fresenius Medical Care AG KGaA (FMS) Germany $14.716B 13.22
Teleflex (TFX) United States $11.964B 19.12
Penumbra (PEN) United States $4.736B 299.29
Integer Holdings (ITGR) United States $2.383B 18.51
Glaukos (GKOS) United States $2.256B 0.00
Nevro (NVRO) United States $1.608B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.313B 23.51
Paragon 28 (FNA) United States $1.281B 0.00
Artivion (AORT) United States $0.772B 83.52